Kenneth Lazarus
Neurology · Fayetteville, GANPI 1689602385
Payments from drug & device makers
Across 1,428 payments — averaging $93.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$50K
- Biohaven Pharmaceuticals, Inc.$24K
- Axsome Therapeutics, Inc.$10K
- Teva Pharmaceuticals USA, Inc.$10K
- Biohaven Pharmaceutical Holding Company Ltd.$9K
- Bausch Health US, LLC$6K
- plus $24K from 54 others
Across 3 payments — averaging $416.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$1K
- Indivior Inc.$250
What the payments were for
- Consulting fees$7,5856%
- Speaking & faculty fees$97,57873%
- Travel & lodging$2,9742%
- Food & beverage$25,10719%
- Education$5530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,797 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 12 | $59,185 |
| QuliptaAtogepant | 23 | $24,078 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,317 |
| Emgality PenGalcanezumab-Gnlm | 27 | $18,131 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 78 | $13,843 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $13,264 |
| Sumatriptan Succinate | 60 | $3,380 |
| Morphine Sulfate ErMorphine Sulfate | 36 | $3,204 |
| Buprenorphine Hcl | 77 | $3,042 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 89 | $2,158 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 59 | $1,604 |
| Gabapentin | 73 | $1,292 |
| Amitriptyline Hcl | 26 | $1,117 |
| Oxcarbazepine | 16 | $1,029 |
| Duloxetine Hcl | 51 | $896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $262 | $59,18512 claims |
| AbbVieQulipta | $50,273 | $24,07823 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $664 | $18,31712 claims |
| Upsher-smith Laboratories LLCTopiramate | $968 | $56565 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 506 neurology providers in Georgia.
Other neurology in Fayetteville
- Wallace GreenFayetteville$59K
- Jonathan LissColumbus$25M
- Marshall NashDecatur$13.6M
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Sandeep VaidLawrenceville$4.2M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.